Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Combimatrix (CBMX) -- Ignore unavailable to you. Want to Upgrade?

To: Paul Lee who wrote (16)	6/12/2003 3:50:13 PM
From: tuck	Read Replies (1) \| Respond to of 237

AFFX announced their SARS array on May 6th. From The Scientist . . . >>Santa Clara, Calif.-based Affymetrix has released a new array designed for complete resequencing of the SARS coronavirus. The GeneChip® CustomSeq™ SARS pathogen detection and resequencing array encompasses the entire 30 kb genome of the virus, allowing full genome resequencing and permitting all mutations to be identified, says Greg Yap, senior director of marketing. Yap notes that although only a few SARS strains have been sequenced to date, this is only a fraction of the number needed for understanding the degree of variation between all versions of the virus, studying how the virus is changing as it spreads, and potentially determining which mutations correspond to more virulent strains. "By doing sequencing across a number of strains of virus, identifying all the possible mutations, you can then associate those mutations with ... [severity of illness] and therefore understand better what kinds of treatments to develop," he explains. --Aileen Constans<< Chers, Tuck